Low-dose methotrexate fails to lower CVD risk

Hopes of an anti-inflammatory benefit dashed

Hoping to tap the anti-inflammatory powers of methotrexate, researchers have failed to show that a low-dose of the drug, used to treat cancer and arthritis, can reduce the risk of heart attack or stroke.

The treatment, detailed Saturday at the American Heart Association’s Scientific Sessions meeting in Chicago and online in the New England Journal of Medicine, also failed to reduce levels of interleukin-1beta, interleukin-6 or C-reactive protein better than placebo in volunteers with stable atherosclerosis.

The trial, known as CIRT, was halted prematurely for futility